Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644394 | 1.00 | POLB (0.44) | POLBL3MBTL1ALDH1A1APPGAA | |
| SCHEMBL14316037 | 0.80 | PGK1 (0.41) | POLBL3MBTL1ALDH1A1APPGAA | |
| SCHEMBL29819187 | 0.79 | MBOAT4 (0.31) | ALDH1A1 | |
| SCHEMBL21713584 | 0.79 | MBOAT4 (0.31) | ALDH1A1 | |
| SCHEMBL2921387 | 0.78 | POLB (0.48) | POLBL3MBTL1ALDH1A1APPGAA | |
| SCHEMBL16426825 | 0.78 | L3MBTL1 (0.38) | POLBL3MBTL1ALDH1A1APPGAA | |
| SCHEMBL21752758 | 0.78 | NPY1R (0.33) | POLBMAPTMEN1KMT2A | |
| SCHEMBL30461434 | 0.78 | L3MBTL1 (0.38) | POLBL3MBTL1ALDH1A1APPGAA | |
| SCHEMBL30888191 | 0.78 | NPY1R (0.33) | POLBMAPTMEN1KMT2A | |
| SCHEMBL24488470 | 0.77 | ALDH1A1 (0.36) | POLBL3MBTL1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568946-A1 | MACROCYCLIC BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024035688-A1 | MACROCYCLIC BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022266193-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3953337-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3796906-A1 | INDANES AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2021-03-31 | — | — | EP | disclosed |
| WO-2020210229-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20180179167-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3307719-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203400-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203400-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051483-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | POLB 3123/4885L3MBTL1 4572/4885ALDH1A1 543/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | POLB 1963/4885L3MBTL1 2438/4885ALDH1A1 799/4885 |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | KEAP1, NFE2L2, GSTK1 | POLB 2215/4885L3MBTL1 1225/4885ALDH1A1 236/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | POLB 3123/4885L3MBTL1 4572/4885ALDH1A1 543/4885 |
| US-20180179167-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | POLB 2212/4885L3MBTL1 3476/4885ALDH1A1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.